Company news

Perspective Therapeutics, Inc. news in 2025

Perspective Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 18, 2025

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium

December 4, 2025

Perspective Therapeutics to Participate in Upcoming December Conferences

November 20, 2025

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

November 10, 2025

Perspective Therapeutics to Participate in Upcoming November Conferences

October 31, 2025

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

October 24, 2025

Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors

October 2, 2025

Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

September 15, 2025

Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer

September 4, 2025

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

September 3, 2025

Perspective Therapeutics to Participate in Upcoming September Conferences

August 26, 2025

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

August 13, 2025

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

July 24, 2025

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

July 15, 2025

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

June 21, 2025

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

June 21, 2025

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

May 30, 2025

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

May 12, 2025

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

May 1, 2025

Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors

April 29, 2025

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

April 23, 2025

Decks in 2025